Texas Roadhouse earnings missed by $0.05, revenue topped estimates
Investing.com - Piper Sandler has reiterated its Overweight rating and $70.00 price target on Exact Sciences (NASDAQ:EXAS) following the company’s strong second-quarter performance. According to InvestingPro data, analysts maintain a strong bullish consensus with price targets ranging from $46 to $90, suggesting significant upside potential from current levels.
The research firm highlighted Exact Sciences’ dominant position in colorectal cancer (CRC) screening and noted the market is rapidly shifting toward noninvasive approaches for detection.
While Piper Sandler acknowledged disappointing recent data on the company’s blood-based test, it emphasized this should not overshadow the core strength of Cologuard, the launch of Cologuard Plus, and the strategic acquisition of Freenome’s CRC test.
The firm expressed its positive outlook on EXAS as a margin expansion story, pointing to contribution margins exceeding 60% for the company.
Exact Sciences recently announced an additional $150 million in cost savings, further supporting Piper Sandler’s bullish stance on the stock.
In other recent news, Exact Sciences Corporation reported its second quarter 2025 earnings, which exceeded analysts’ expectations. The company posted an earnings per share (EPS) of -$0.01, significantly better than the forecasted -$0.13, resulting in an EPS surprise of 92.31%. Revenue also surpassed projections, reaching $811.1 million compared to the anticipated $773.8 million, marking a 4.82% surprise. These figures highlight a strong financial performance for the quarter. Despite the positive earnings report, Exact Sciences’ stock closed lower than the previous session. There were no recent announcements regarding mergers or acquisitions for the company. Analyst firms have not recently upgraded or downgraded the stock, leaving the company’s rating unchanged. These developments provide investors with the latest insights into Exact Sciences’ financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.